Germline genetic testing can benefit all cancer patients as a routine practice in cancer care New data to be presented at 2021 ASCO Annual Meeting highlight need for increased germline testing in all cancer patients regardless of medical policy
News provided by
Share this article
Share this article
SAN FRANCISCO, May 25, 2021 /PRNewswire/ Invitae Corporation (NYSE: NVTA), a leading medical genetics company, is presenting multiple studies in multiple cancer types at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting showing all cancer patients can benefit from germline genetic testing to guide their care. The use of genetic information informs changes in cancer care, increases access to precision therapies and guides screening for high-risk individuals and their family members. Earlier detection and precision therapies are critical to increase survivorship for people with cancer, yet the oncology community has been slow to adopt routine testing.